Patients with early-onset primary Sjögren’s syndrome have distinctive clinical manifestations and circulating lymphocyte profiles

Lin Wei¹*, MD, PhD, Xin Zhifei²*, MS, Ning Xiaoran¹, MS, Liu Meilu¹, MS, Li Yang³, MS, Liu Yixuan¹, MS, Ren Xiuying¹, MS, Su Yashuang¹, MS, Cao Jingjing¹, MS, Guo Shaoying⁴, MS, Yang Liu⁴, MS, Sun Lijun¹, MS, Zhang Fengxiao¹, MS, Zhang Wen⁵, MD, PhD

1. Department of Rheumatology and immunology, Hebei General Hospital, Shijiazhuang, 050017, China;
2. Department of Thoracic surgery, Hebei General Hospital, Shijiazhuang, 050017, China;
3. Department of Oncology, Hebei General Hospital, Shijiazhuang, 050017, China;
4. Department of Graduate School, Hebei Medical University, Shijiazhuang, 050017, China;
5. Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Beijing, 100730, China.

* Lin Wei and Xin Zhifei have contributed equally to this work.

Key Indexing Terms: Sjögren’s syndrome, onset age, prognoses

The source(s) of support in the form of grants or industrial support:
This work was funded by the grant from the National Nature Science Foundation of China (No. 81801630) and the National Nature Science Foundation of Hebei Province (No. H2018307047).

Conflict of interest: The authors declare no potential conflicts of interest.

Corresponding author’s name, address, and email:
Please address correspondence to: Zhang Fengxiao,
Department of Rheumatology and immunology, Hebei General Hospital,
No. 348 Heping West Road, Shijiazhuang, Hebei, China, 050017
E-mail: zfx9911@163.com

Statement of ethics and consent:
This study was approved by the Clinical Research Ethics Committee of the Hebei General Hospital (NO.20160707), and informed consent for publication was obtained from the patients.

Data availability statement: All data relevant to the study are included in the article or uploaded as online supplementary information. The data that support the findings of this study are available from the corresponding authors on reasonable request.
Abstract

**Objectives:** To further investigate the clinical characteristics and circulating lymphocyte profiles of patients with early-onset primary Sjögren’s syndrome (pSS).

**Method:** Data of 333 patients with pSS were analyzed retrospectively. Early onset was defined as a pSS diagnosis at an age of 35 years or younger. The clinical, laboratory, and immunophenotypic profiles of peripheral blood lymphocyte subsets were compared between early- and later-onset pSS.

**Results:** Thirty-six (10.81%) patients matched the definition of early-onset pSS, with age at disease onset being 28.97 ± 5.53 years. Elevated serum IgG level (77.14% vs 31.16%, p < 0.001), low C3 (41.67% vs 20.20%, p = 0.004) and C4 levels (27.78% vs 6.40%, p < 0.001), anti-SSA positivity (91.67% vs 51.85%, p < 0.001), and anti-SSB positivity (50% vs 20.54%, p < 0.001) were more frequent in early-onset patients. The frequencies of hematological (80.56% vs 52.53%, p = 0.001), renal (19.44% vs 5.05%, p = 0.005), and mucocutaneous involvement (50% vs 22.56%, p < 0.001) were significantly higher in the early-onset pSS group, which showed a higher ESSDAI (11(6.25-17) vs 7(3-12); p = 0.003), compared with the later-onset group. In addition, profound CD4+ T-cell lymphopenia was found in patients with early-onset.

**Conclusions:** Patients with early-onset pSS have distinctive clinical manifestations and greater activation of the cellular immune system, present with more severe clinical symptoms and immunological features, have increased activation of circulating T cells, and have an unfavorable prognosis. Thus, they require more positive treatment with glucocorticoids and/or immunosuppressants and merit closer follow-up and regular monitoring.

**Keywords:** Early-onset; Primary Sjögren’s syndrome; ESSDAI; progress; lymphocyte profile

**Key messages:**
1. Early-onset pSS patients have distinctive clinical manifestations and greater activation of the cellular immune system.
2. Early-onset pSS patients exhibit a higher intensity of the disease (as evaluated by ESSDAI).
3. Patients with early-onset pSS need more positive treatment and closer follow up.
Introduction

Primary Sjögren syndrome (pSS) is a chronic systemic rheumatic disease characterized by lymphoplasmacytic infiltration of the salivary and lachrymal glands, presenting as sicca syndrome(1). pSS can affect virtually all organs, ranging from mild inflammatory arthralgia to life-threatening manifestations such as pulmonary interstitial fibrosis or nervous system involvement (2, 3). Therefore, a different therapeutic strategy based on both the sicca and systemic manifestations of patients with pSS should be considered.

pSS is a common disorder that affects 0.1% to 4.8% of the general population. pSS can occur in people of all ages, but it most frequently affects women between the fourth and sixth decades of life, with a female to male ratio of 9:1(4, 5). The heterogeneous presentation of autoimmune diseases (including rheumatoid arthritis, systemic lupus erythematosus (SLE), and pSS has encouraged the investigation of subsets of patients with specific features, courses, and outcomes. Previous studies have attempted to determine whether age at onset is associated with a particular expression in different autoimmune diseases. Patients with early-onset rheumatoid arthritis (RA) have been found to be less active and suffer from more disabilities (6). Patients with early-onset SLE had a higher SLE Disease Activity Index 2000 and more renal features, neurologic manifestations, and immunologic abnormalities than those with late-onset SLE (7). It is of great clinical importance to investigate the effect of age at onset, as it may affect the clinical progress of pSS. However, early-onset pSS appears to be less frequent, with an incidence ranging from 11.4% to 19%, and only a few studies have so far focused on the relationship between the clinical and laboratory findings and age at onset in pSS patients(8-11). Further, the existing data on his issue are controversial. Moreover, information on early-onset pSS in Northeast Asia, and specifically China, is limited.

To better understand whether any relationship exists between disease manifestations and age at onset in Chinese pSS patients, this retrospective study enrolled enrolled 333 consecutive, newly-diagnosed pSS patients. The demographic data, immune serological features, clinical profiles, disease activity, and different treatment modalities in patients with early-onset pSS and those with late-onset pSS were analyzed and compared. In the present study, we aimed to seek evidence for the greater immune disturbance in patients with early-onset pSS. For that purpose, the distribution of various lymphocyte subsets in the peripheral blood of different age-onset pSS patients was investigated. The patients were also followed up, and their prognoses were evaluated.

Materials and methods

Patients

A monocentric retrospective study was carried out, and 333 newly diagnosed pSS patients treated at the Department of Rheumatology of Hebei General Hospital between September 2016 and February 2019 were included. All subjects with pSS were classified according to the American-European Consensus Group classification criteria of 2002(2). Those who did not have chronic hepatitis C virus human immunodeficiency virus infection, previous lymphoproliferative processes, and associated systemic autoimmune diseases (such as RA, SLE, systemic sclerosis, et al) were enrolled in the study. All included patients had an Asian phenotype. The enrolled pSS patients were divided into two groups based on whether they had been diagnosed with pSS when they were ≤ 35 years old (early onset) or older than 35 years (later onset). All study participants provided written informed consent, and the study design was approved by the Ethics Board of Hebei General Hospital (approval ID: NO.2016070).
Clinical variables
The clinical and laboratory variables of pSS patients at onset, before starting any treatment, were retrospectively reviewed. The levels of biological parameters were recorded from the case files and included data on erythrocyte sedimentation rate, C-reactive protein (CRP), immunoglobulins (IgG, IgA, and IgM), complement (C3 and C4), blood protein electrophoresis, rheumatoid factor (RF), and antinuclear antibodies (ANAs). All tests were performed at the clinical laboratory, and all data were available. Clinical features rigorously assessed included age at diagnosis, disease duration, and clinical manifestations. Extraglandular involvement was evaluated according to the 2010 EULAR SS Disease Activity Index (ESSDAI)(12, 13). Mucocutaneous involvement was defined as cutaneous vasculitis (demonstrated by cutaneous purpura and skin biopsy); digestive involvement was defined as the appearance of symptoms and signs associated with impaired digestive function, including esophageal impairment, gastroesophageal reflux, altered liver function tests, and/or abnormal liver biopsy. The ESSDAI as assessed to measure disease activity at diagnosis and at last follow-up. Disease activity was defined as low, moderate, and high, with scores of <5, 5-13, and ≥ 14, respectively(14). Clinical and laboratory data were collected and according to a standard protocol(15).

The duration of follow-up was defined as the interval from diagnosis until the date of the latest data collection (January 2021) or the date of death. Patients were usually evaluated every 3 or 6 months based on clinical judgement. Information regarding vital signs and causes of death was obtained from medical records.

Cell surface staining and flow cytometric analysis
Fluorescence-activated cell sorting (FACS) analysis of lymphocyte subsets was performed according to a standard protocol before any treatment. In brief, erythrocytes were lysed, and cells were harvested and washed twice and stained for 20 min at 4°C using specific antibodies. Cells were incubated with antibodies against CD3, CD4, CD8, CD16, CD56, CD45, and CD19 (all Becton Dickinson, San Diego, CA, USA) and subsequently washed and resuspended in phosphate-buffered saline prior to analysis. The stained cells were measured with a FACS Canto flow cytometer (Becton Dickinson, San Jose, CA, USA), and the data were analyzed using FlowJo Software (Treestar, Ashland, OR, USA).

Statistical analysis
Statistical analysis was carried out using SPSS 25.0 (IBM orp., Armonk, NY, USA). The chi-squared test or Fisher’s exact test was used for comparisons, and categorical data are summarized using frequencies and percentages. The quantitative data are presented as means ± standard deviations when normally distributed and as medians and interquartile ranges (IQR) when not normally distributed. In the between-group comparisons, the quantitative data were analyzed using Student’s t-test or the Mann–Whitney U test as appropriate. The correlations between variables were evaluated with Spearman’s rank correlation coefficient. p < 0.05 was considered significant.

RESULTS
Demographic data
In total, 333 patients with pSS were enrolled in this study, with more female than male patients (310 versus 23). Although the predominance of females among those with early-onset pSS (35 of 36 [97.2%]) was higher than that observed in later-onset pSS (275 of 297 [92.5%]), the difference did not reach statistical significance (p = 0.49). The median [IQR] age at disease diagnosis was 29 [26–
years in the early-onset group. Furthermore, disease duration was shorter in the early-onset pSS group (p < 0.001). (Table 1)

**Laboratory characteristics**

As shown in Table 1, a lower hemoglobin level (113.5 (102.25–121.75) g/L vs. 123 (111–133) g/L, p = 0.001), higher serum IgG level (21.7 (19.2–30.58) g/L vs 14.9 (12–18.30) g/L, p < 0.001), and higher serum RF level (56.40 (17.0–218) IU/L vs 14.60 (10.6–56.75) IU/L, p < 0.001) were observed in the early-onset group. An elevated serum IgG level (77.14% vs 31.16%, p < 0.001), low C3 level (41.67% vs 20.20%, p = 0.004), low C4 level (27.78% vs 6.40%, p < 0.001), RF positivity (74.29% vs 44.93%, p = 0.001), anti-Ro52 positivity (88.89% vs 56.57%, p < 0.001), anti-RNP positivity (27.78% vs 9.76%, p = 0.004), anti-Ro/SSA positivity (91.67% vs 51.85%, p < 0.001), and anti-La/SSB positivity (50% vs 20.54%, p < 0.001) were more frequently observed in patients with early-onset disease. In addition, there was no between-group difference regarding the presence of a monoclonal peak (p = 0.99). Moreover, the positive ANA rate was not significantly different between the two groups. Similarly, platelet counts, CRP value, and anti-ACA positivity did not significantly differ between the groups at the time of diagnosis. Meanwhile, a focus score of ≥1 at histological evaluation of the minor salivary gland showed no between-group difference (Table 1).

**Clinical manifestations**

When we evaluated the clinical findings at the time of pSS diagnosis (Figure 1 and Sup-Table 1), the frequencies of hematological (80.56% vs 52.53%, p = 0.001), renal (19.44% vs 5.05%, p = 0.005), and mucocutaneous (50% vs 22.56%, p < 0.001) involvement were significantly higher in the early-onset group. There was no significant difference in terms of xerostomia, xerophthalmia, arthritis, pulmonary involvement, nervous system involvement, or digestive system involvement between the two groups.

**Lymphocyte subset distribution in the peripheral blood of patients with early- and later-onset pSS**

Patients with early-onset pSS had a significantly lower number of circulating lymphocytes compared with those in the later-onset group (1.22 (1.00-1.59) x 10⁹/L vs. 1.52 (1.12-1.89) x 10⁹/L, p = 0.03). We further conducted immune phenotyping of different age-onset pSS patients with flow cytometry to investigate their immunological status. The distributions of T cells, B cells, and NK cells in patients with early-onset and later-onset disease are shown in Figure 2 and Sup-Table 2. We found a significance decrease in absolute numbers of CD16/CD56⁺ NK cells in early-onset patients (106.18 [78.65-135.66]/ul vs 192.01 [128.40-297.81]/ul, p < 0.001), whereas CD3⁺ T cells and CD19⁺ B cells were comparable between the groups (p > 0.05). Because lymphopenia was mostly the result of T-cell deficiency, we performed a further sub-analysis of T cells and observed a more pronounced reduction of CD4⁺ T cells compared with their CD8⁺ counterparts. The between-group comparison revealed that profound CD4⁺ T-cell lymphopenia and decreased numbers of CD16/CD56⁺ NK cells were the most distinguishing features of the early-onset group. Besides, the ESSDAI inversely correlated with the absolute number of CD3⁺ T cells, CD4⁺ T cells, CD19⁺ B cells, and CD16/CD56⁺ NK cells.

**Disease activity, treatment, and prognosis**

Patients with early-onset disease showed a higher ESSDAI (11 (6.25-17) vs 7 (3-12); p = 0.003). Most of the patients (52.78%) in the early-onset group had moderate disease activity at diagnosis of pSS; 11.11% had low disease activity, and 36.11% had high disease activity. These values were
significantly different in the later-onset pSS group (46.46%, 30.30%, and 23.23%, respectively, p = 0.01).

Regarding therapy, prednisone/methylprednisolone were more often prescribed in the early-onset group (38.89% vs. 21.55%, p = 0.02). Immunosuppressive therapy was started in 19/36 patients; 10 were treated with leflunomide, 5 with mycophenolate mofetil, 2 with iguratimod, 1 with cyclosporin A, and 1 with cyclophosphamide. When compared with the later-onset group, more patients in the early-onset group received mycophenolate mofetil (13.89% vs. 0.34%, p < 0.001). Therapy did not differ between the two groups regarding other immunosuppressants (Sup-Table 3).

The two groups of patients had a similar duration of follow-up (30.06 ± 8.65 months vs. 33.02 ± 8.94 months, p = 0.33). At the last follow-up visit, the ESSDAI in patients with early-onset was still higher than that in patients with later-onset patients (6 (2-10) vs 5 (0-8); p = 0.02), which was significantly lower compared to the ESSDAI at diagnosis (p < 0.001). Moreover, disease activity was low in 9/35 (25.71%) patients, moderate in 24/35 (68.57%), and high in 2/31 (5.71%). Improvement in the ESSDAI at the last follow-up visit, compared to that at baseline, was also observed in the later-onset group (5 (0-8) vs. 7 (3-12); p < 0.001), and disease activity was low in 133/278 (47.84%), moderate in 119/278 (42.81%), and high in 26/278 (9.35%) patients (Figure 3 and Sup-Table 4).

During follow-up, more pSS patients developed SLE in the early-onset group (2.78%) than in the later-onset group (1.74%), although the difference was not statistically significant (p = 0.51). Besides, no patient was diagnosed with lymphoma or other malignancies during the follow-up. Finally, four patients (1.20%) in later-onset group died; death was due to pSS complications in one of these patients.

**Discussion**

It is well known that pSS is a heterogeneous entity with geographic/ethnic origin, genetic, environmental, and socioeconomic variations, which may drive the different biological and immunological responses. To date, studies investigating the prognostic factors of early-onset pSS have centered on the clinical and laboratory features at diagnosis. The present study was the first to evaluate the differences between patients with early-onset and later-onset pSS in China. Our study uncovered that patients with early-onset pSS had distinctive demographic features and circulating lymphocyte profiles; they presented with more severe clinical symptoms and immunological features than those with later-onset. Our findings also suggested that patient with early-onset pSS should be monitored regularly because of their potential to develop SLE.

Our study found that patients with early-onset had distinctive demographic features; they had a significantly shorter disease duration than those with later-onset. Moreover, a strikingly more severe disease activity characterized early-onset pSS disease, with the frequencies of hematological, renal, and mucocutaneous involvement (80.56%, 19.44%, and 50%, respectively) being significantly higher than those in the later-onset group. In a previous study on a Spanish cohort of 144 patients with 13 patients < 35 years old, the early-onset group had a higher prevalence of articular involvement (31%), peripheral neuropathy (23%), cutaneous vasculitis (23%), and RP (23%)(8). Anquetil et al. investigated 395 consecutive patients with pSS recruited from a French nationwide multicenter prospective cohort including 55 patients with early-onset disease. These patients presented a significantly higher frequency of salivary gland enlargement (SGE) (47.2%), adenopathy (25.5%), purpura (23.6%), and renal involvement (16.4%) than patients who at disease diagnosed age >35 years (9). Another retrospective study of a multicenter population of 1997
consecutive pSS patients, including Italians and Greeks, showed that patients with early-onset pSS presented more frequently with SGE (39.1%), lymphadenopathy (20.7%), and Raynaud’s phenomenon (36.6%) (8). The immunological profile of early-onset pSS highlights the presence of anti-SSA and anti-SSB antibodies, RF positivity, low C3 and C4 levels, and hypergammaglobulinemia. Similar findings have been described by previous groups (8-10). Although they shared some common features, patients from different ethnic groups included in the early-onset pSS group did not all present with the same manifestations, suggesting that genetic, environmental, and socioeconomic variations are involved in the biological and immunological responses.

A previous study suggested that peripheral lymphopenia was associated with higher disease activity and mortality in pSS patients (16). In the present study, for the first time, we compared the distribution of circulating lymphocyte subsets in different age-onset patients with pSS. In this study, we found that patients with early-onset pSS had a significantly reduced lymphocyte count compared with those in the later-onset group. A lower number of T cells was more pronounced in the early-onset group and could be explained by profound CD4+ T-cell lymphopenia. This may partly shed light on the reason behind the marked disturbances in the serological aspects of the early-onset group, as systemic immune activation results in increased levels of circulating autoantibodies and immune complexes and a severe inflammatory condition. The main reason for the marked CD4+ T-cell lymphopenia in different age-onset pSS patients needs to be further studied. Interestingly, we also found CD16/CD56+ NK cells, innate lymphoid cells that exhibit a potential regulatory role in exocrine gland tissues and the peripheral blood of pSS disease (17, 18), were significantly decreased in the early-onset group. Our data provide evidence that the immunological status may contribute to the distinct features of different age-onset pSS patients.

SLE and pSS have several similar clinical and serological aspects (19-22), which often hamper distinguishing between the two disorders (23). Recent studies have suggested that both disorders share many etiopathogenic links, including genetic factors (24-26), epigenetic alterations (26), and activation of T and B-cells (22). Conversely, previous studies have reported that patients with early-onset pSS are more likely to develop SLE than those with later-onset pSS. In a retrospective study investigating 55 SS/SLE patients attending the Department of Rheumatology of Peking Union Medical College Hospital, Yang et al. revealed that compared to the control pSS group, SS/SLE patients had a younger age at onset (31 ± 12 vs. 39 ± 11 years, p = 0.001) (27). These results suggested that long-term observation is required because patients with early-onset pSS have the potential to develop SLE.

Mortality in pSS cohorts is mainly attributed to systemic disease and lymphoma (28, 29). In light of the current data, systemic involvement, present in almost 70%-80% of the patients at diagnosis, plays a key role in the prognosis of pSS. Brito-Zeron et al evaluated the potential association between baseline systemic activity and mortality using the ESSDAI for the first time and suggested that high baseline systemic activity may be related to a higher risk of death (16). In addition, disease activity also played a role in the development of lymphoma (30). In our study, the early-onset group showed a significantly higher ESSDAI. In contrast, clinical predictors for the development of lymphoma (31, 32) (lower age at diagnosis, positive RF, anti-Ro/SSA positivity, hypocomplementemia, and hyperglobulinemia) were also more common in the early-onset pSS group. These features further support the theory that in early-onset pSS, patients have a higher frequency of lymphoproliferative disease development and mortality.
Overall, after a more intensive treatment, systemic disease activity significantly decreased over time in patients with early-onset, with approximately 90% of patients retaining low and moderate disease activity at the last follow-up. Therefore, better disease stratification is warranted. Patients who are at higher risk for a worse outcome must be identified and receive more vigorous treatment for disease improvement.

This study had several limitations. First, the retrospective nature of the data comprises an important limitation that may have affected the conclusions. Information on the cryoglobulin status was insufficient because of the lack of routine evaluation of cryoglobulin in our patients. In addition, the heterogeneity of Chinese pSS patients, possibly because of genetic and environmental differences, is another limitation that may have also affected the data analysis. Finally, patients from a single center were enrolled, which may have led to selection bias.

**Conclusions**

In conclusion, our study showed that unlike patients with later-onset pSS, those with early-onset pSS have distinctive clinical manifestations and greater activation of the cellular immune system, present with more severe clinical symptoms and immunological features, have increased activation of circulating T and B cells, and have a worse prognosis. Therefore, they require more intensive treatment with glucocorticoids and/or immunosuppressants and stricter monitoring.

**Acknowledgment**

The authors would like to thank Dr. Wang Zhihua for excellent flow cytometry work.

**Author Contributions**

Conceptualization, LW, ZF, NX, and ZW; investigation, XZ, LM, SY and RX; resources, GS, YL; writing, LW, CJ, LY; supervision, ZF, SL; funding acquisition, LW. All authors have read and agreed to the published version of the manuscript.
Table 1. Baseline demographic and laboratory characteristics of the groups according to age at pSS diagnosis

|                        | Early-onset group (n = 36) | Later-onset group (n = 297) | P value |
|------------------------|---------------------------|-----------------------------|---------|
| **Demographic characteristics** |                           |                             |         |
| Sex (F/M)              | 35:1                      | 275:22                      | 0.49    |
| Age at onset, years    | 28.97 ± 5.53              | 56.95 ± 10.65               | < 0.001 |
| Disease duration, months | 24 (4–45)                | 60 (12–120)                 | < 0.001 |
| **Laboratory findings** |                           |                             |         |
| WBC (×10^9/L)          | 4.72 (3.72–6.55)          | 4.96 (3.97–6.24)            | 0.81    |
| Neutrophil count (×10^9/L) | 3.65 (2.08–4.73)        | 2.93 (2.19–4.17)            | 0.49    |
| Lymphocyte count (×10^9/L) | 1.22 (1.00–1.59)         | 1.52 (1.12–1.89)            | 0.03    |
| Hemoglobin (g/L)       | 113.5 (102.25–121.75)    | 123 (111–133)               | 0.001   |
| Platelet counts (×10^9/L) | 240 (159.5–298)       | 223 (179–264.5)             | 0.49    |
| NLR                    | 2.73 (1.67–3.51)          | 1.98 (1.41–2.83)            | 0.05    |
| PLR                    | 161.83 (118.76–269.34)   | 143.14 (109.65–197.07)      | 0.07    |
| ESR (mm/1h)            | 26 (15–51)                | 17 (8–35)                   | 0.01    |
| CRP (mg/L)             | 1.94 (0.52–11.91)         | 3.30 (1.24–4.18)            | 0.31    |
| RF (IU/L)              | 56.40 (17.0–218)          | 14.60 (10.6–56.75)          | < 0.001 |
| IgG (g/L)              | 21.7 (19.2–30.58)         | 14.9 (12–18.30)             | < 0.001 |
| IgA (g/L)              | 3.0 (2.4–4.14)            | 2.73 (1.91–3.53)            | 0.19    |
| IgM (g/L)              | 1.24 (0.9–1.64)           | 1.14 (0.79–1.61)            | 0.19    |
| C3 (g/L)               | 0.93 (0.82–1.11)          | 1.08 (0.93–1.21)            | 0.001   |
| C4 (g/L)               | 0.17 (0.10–0.20)          | 0.20 (0.16–0.24)            | 0.001   |
| Elevated ESR (n, %)    | 22, 62.86%                | 129, 45.10%                 | 0.05    |
| Elevated CRP (n, %)    | 10, 28.57%                | 53, 19.06%                  | 0.15    |
| Hyper-IgG (n, %)       | 27, 77.14%                | 91, 31.16%                  | < 0.001 |
| Monoclonal peak (n, %) | 1/34, 2.94%               | 7/242, 2.89%                | 0.99    |
| Low C3 (n, %)          | 15, 41.67%                | 60, 20.20%                  | 0.004   |
| Low C4 (n, %)          | 10, 27.78%                | 19, 6.40%                   | < 0.001 |
| RF (+) (n, %) *        | 26, 74.29%                | 124, 44.93%                 | 0.001   |
| ANA (+) (n, %) **      | 32, 88.89%                | 231, 77.78%                 | 0.12    |
| Anti-RNP (+) (n, %)    | 10, 27.78%                | 29, 9.76%                   | 0.004   |
| Anti-Ro52 (+) (n, %)   | 32, 88.89%                | 168, 56.57%                 | < 0.001 |
| Anti-Ro/SSA (+) (n, %) | 33, 91.67%                | 154, 51.85%                 | < 0.001 |
| Anti-La/SSB (+) (n, %) | 18, 50%                   | 61, 20.54%                  | < 0.001 |
| Anti-ACA (+) (n, %)    | 1, 2.78%                  | 44, 14.81%                  | 0.05    |
Pathological MSG with focus score $\geq 1$ (n, %)

|                | Early-onset | Later-onset |
|----------------|-------------|-------------|
| Pathological MSG with focus score $\geq 1$ | 36, 100%    | 273, 95.12% |
| ESSDAI         | 11 (6.25–17)| 7 (3–12)    |

Values are presented as n, mean ± standard deviation, median (interquartile range), or number (%). All p values were evaluated by comparing between the patients with early-onset and those with later-onset disease using the chi-squared test, Fisher’s exact test, Student’s t-test, or Mann–Whitney’s U-test, as appropriate. pSS, primary Sjögren’s syndrome; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; IgG, immunoglobulin IgG; IgA, immunoglobulin IgA; IgM, immunoglobulin IgM; RF, rheumatoid factor; ANA, antinuclear antibodies; ACA, anti-centromere antibodies; MSG, minor salivary gland.

*p positive RF >20 IU/ml; **positive for ANA titers $\geq 1$:320.

Figure 1. Clinical manifestations of the two groups of patients according to age at pSS diagnosis. **p < 0.01, ***p < 0.001.
Figure 2. Immunological status in patients with early-onset pSS

Graphs show (A) absolute numbers of CD3$^+$ T cells, CD4$^+$ T cells, CD8$^+$ T cells, CD19$^+$ B cells, and CD16/CD56$^+$ NK cells in the early-onset and later-onset groups; (B) prevalence of CD3$^+$ T cells, CD4$^+$ T cells, CD8$^+$ T cells, CD19$^+$ B cells, and CD16/CD56$^+$ NK cells in the lymphocytes of the early-onset and later-onset groups; (C) correlation of the ESSDAI with lymphocyte count in pSS patients; (D) correlation of the ESSDAI with absolute numbers of CD3$^+$ T cells in pSS patients; (E) correlation of the ESSDAI with the prevalence of CD4$^+$ T cells in the lymphocytes of pSS patients; (F, G, H, I) correlation of the ESSDAI with the absolute numbers of CD4$^+$ T cells, CD8$^+$ T cells, CD19$^+$ B cells, and CD16/CD56$^+$ NK cells in pSS patients. Lines between bars indicate significantly altered fractions. **p < 0.01, ***p < 0.001.
Figure 3. Disease activity of patients with pSS as grouped by age of onset at baseline and at the last follow-up visit.

Graphs show the ESSDAI (A) at baseline and at the last follow-up visit for all patients, (B) between the early-onset group and later-onset group at baseline, (C) between early-onset group and later-onset group at the last follow-up visit, (D) at baseline and at the last follow-up visit for the early-onset group, and (E) at baseline and at the last follow-up visit for the later-onset group. Graphs show the improvements of disease activity at baseline and at the last follow-up visit (F) in those with early-onset patients and (G) with later-onset patients. *p < 0.05, **p < 0.01, ***p < 0.001.
Data Supplements

Sup-Table 1. Clinical features of the two groups of patients according to age at pSS diagnosis

| Variables                          | Early-onset group (n = 36) | Later-onset group (n = 297) | P value |
|------------------------------------|----------------------------|-----------------------------|---------|
| Xerostomia                         | 28 (77.78%)                | 262 (88.22%)                | 0.11    |
| Xerophthalmia                      | 22 (61.11%)                | 224 (75.42%)                | 0.07    |
| Salivary gland enlargement         | 7 (19.44%)                 | 31 (10.44%)                 | 0.16    |
| Hematological involvement          |                            |                             |         |
| Thrombocytopenia                   | 4 (11.11%)                 | 16 (5.39%)                  | 0.25    |
| Leukopenia                         | 10 (27.78%)                | 54 (18.18%)                 | 0.17    |
| Lymphopenia                        | 13 (36.11%)                | 75 (25.25%)                 | 0.16    |
| Anemia                             | 20/55.56                   | 102/34.34                   | 0.01    |
| Arthritis                          | 13 (36.11%)                | 133 (44.78%)                | 0.32    |
| Lung involvement                   | 4 (11.11%)                 | 70 (23.57%)                 | 0.09    |
| Renal involvement                  | 7 (19.44%)                 | 15 (5.05%)                  | 0.005   |
| Digestive involvement             | 2 (5.56%)                  | 15 (5.05%)                  | 0.70    |
| Nervous system involvement         | 2 (5.56%)                  | 39 (13.13%)                 | 0.28    |
| Mucocutaneous involvement         | 18 (50%)                   | 67 (22.56%)                 | < 0.001 |
| Raynaud’s phenomenon               | 8 (22.22%)                 | 30 (10.10%)                 | 0.05    |
| Lymphatic system involvement       | 4 (11.11%)                 | 29 (9.76%)                  | 0.77    |
| ESSDAI                             | 11 (6.25–17)               | 7 (3–12)                    | 0.003   |

Sup-Table 2. Percentages and absolute counts of lymphocyte subsets in the peripheral blood of patients with early- and later-onset pSS

|                          | Early-onset group (n = 31) | Later-onset group (n = 215) | P value |
|--------------------------|----------------------------|-----------------------------|---------|
| Prevalence of CD3⁺ cells in lymphocytes | 73.3 [67.45–79.51] | 73 [65.29–78.86] | 0.33    |
| Absolute number of CD3⁺ cells (/ul) | 906.30 [671.05–1199.85] | 1073.93 [776.59–1326.79] | 0.12    |
| Prevalence of CD4⁺ cells in lymphocytes | 34.08 ± 9.45 | 39.01 ± 9.91 | 0.01    |
| Absolute number of CD4⁺ cells (/ul) | 391.72 [288.85–558.83] | 571.76 [399.16–772.26] | 0.002   |
| Prevalence of CD8⁺ cells in lymphocytes | 30.75 [23.50–42.97] | 27.44 [22.02–35.09] | 0.01    |
| Absolute number of CD8⁺ cells (/ul) | 415.21 [241.29–593.53] | 368.19 [278.72–527.50] | 0.48    |
| Prevalence of CD19⁺ cells in lymphocytes | 14.48 [8.10–17.19] | 11.60 [7.48–16.17] | 0.20    |
| Absolute number of CD19⁺ cells (/ul) | 172.53 [90.72–244.76] | 164.09 [95.46–256.87] | 0.74    |
| Treatment (n, %) | Early-onset | Later-onset | p   |
|-----------------|-------------|-------------|-----|
| Prednisone/methylprednisolone | 14, 38.89% | 64, 21.55% | 0.02 |
| Leflunomide     | 10, 27.78% | 72, 24.24% | 0.64 |
| Mycophenolate mofetil | 5, 13.89% | 1, 0.34% | < 0.001 |
| Igluatimod      | 2, 5.56%   | 12, 4.04%  | 0.65 |
| Cyclosporin A   | 1, 2.78%   | 7, 2.36%   | 0.60 |
| Cyclophosphamide| 1, 2.78%   | 3, 1.01%   | 0.37 |
| Hydroxychloroquine | 31, 86.11% | 225, 75.76% | 0.16 |
Sup-Table 4. Disease activity at baseline and at the last follow-up visit

| Disease activity | Low      | Moderate | High      | p       |
|------------------|----------|----------|-----------|---------|
|                  | (n, %)   |          |           |         |
| Baseline         |          |          |           |         |
| Early-onset      | 4, 11.11%| 19, 52.78%| 13, 36.11%| 0.003\textsuperscript{a} |
| Last Follow-up   | 9, 25.71%| 24, 68.57%| 2, 5.71%  | < 0.001\textsuperscript{b} |
| Baseline         | 90, 30.30%| 138, 46.46%| 69, 23.23%| 0.012\textsuperscript{c} |
| Later-onset      | 133, 47.84%| 119, 42.81%| 26, 9.35% | 0.052\textsuperscript{d} |

a. baseline vs. last follow-up visit for early-onset group
b. baseline vs. last follow-up visit for later-onset group
c. early-onset vs. later-onset groups at baseline
d. early-onset vs. later-onset groups at last follow-up visit

Appendix (Non-author collaborator list only)
None.

References

1. Brito-Zeron P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X, et al. Sjogren syndrome. Nat Rev Dis Primers. 2016;2:16047.
2. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554-8.
3. Baldini C, Pepe P, Quartuccio L, Priori R, Bartoloni E, Alunno A, et al. Primary Sjogren's syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology (Oxford). 2014;53(5):839-44.
4. Patel R, Shahane A. The epidemiology of Sjogren's syndrome. Clin Epidemiol. 2014;6:247-55.
5. Parisis D, Chivasso C, Perret J, Soyfoo MS, Delporte C. Current State of Knowledge on Primary Sjogren's Syndrome, an Autoimmune Exocrinopathy. J Clin Med. 2020;9(7).
6. El-Labban AS, Omar HA, El-Shereif RR, Ali F, El-Mansoury TM. Pattern of Young and Old Onset Rheumatoid Arthritis (YORA and EORA) Among a Group of Egyptian Patients with Rheumatoid Arthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2010;3:25-31.
7. Aljohani R, Gladman DD, Su J, Urowitz MB. Disease evolution in late-onset and early-onset systemic lupus erythematosus. Lupus. 2017;26(11):1190-6.
8. Goules AV, Argyropoulou OD, Pezoulas VC, Chatzis L, Critselis E, Gandolfo S, et al. Primary Sjogren's Syndrome of Early and Late Onset: Distinct Clinical Phenotypes and Lymphoma
9. Anquetil C, Hachulla E, Machuron F, Mariette X, Le Guern V, Vittecoq O, et al. Is early-onset primary Sjogren's syndrome a worse prognosis form of the disease? Rheumatology (Oxford). 2019;58(7):1163-7.
10. Ramos-Casals M, Cervera R, Font J, Garcia-Carrasco M, Espinosa G, Reino S, et al. Young onset of primary Sjogren's syndrome: clinical and immunological characteristics. Lupus. 1998;7(3):202-6.
11. Botios C, Furlan A, Ostuni P, Sfriso P, Andretta M, Ometto F, et al. Elderly onset of primary Sjogren's syndrome: clinical manifestations, serological features and oral/ocular diagnostic tests. Comparison with adult and young onset of the disease in a cohort of 336 Italian patients. Joint Bone Spine. 2011;78(2):171-4.
12. Seror R, Theander E, Brun JG, Ramos-Casals M, Valim V, Dorner T, et al. Validation of EULAR primary Sjogren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis. 2015;74(5):859-66.
13. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis. 2010;69(6):1103-9.
14. Seror R, Bootsma H, Saraux A, Bowman SJ, Theander E, Brun JG, et al. Defining disease activity states and clinically meaningful improvement in primary Sjogren's disease with EULAR primary Sjogren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis. 2016;75(2):382-9.
15. Ramos-Casals M, Brito-Zeron P, Solans R, Camps MT, Casanovas A, Sopena B, et al. Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology (Oxford). 2014;53(2):321-31.
16. Brito-Zeron P, Kostov B, Solans R, Fraile G, Suarez-Cuervo C, Casanovas A, et al. Systemic activity and mortality in primary Sjogren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. Ann Rheum Dis. 2016;75(2):348-55.
17. Izumi Y, Ida H, Huang M, Iwanaga N, Tanaka F, Aratake K, et al. Characterization of peripheral natural killer cells in primary Sjogren's syndrome: impaired NK cell activity and low NK cell number. J Lab Clin Med. 2006;147(5):242-9.
18. Ming B, Wu T, Cai S, Hu P, Tang J, Zheng F, et al. The Increased Ratio of Blood CD56bright NK to CD56dim NK Is a Distinguishing Feature of Primary Sjögren’s Syndrome. Journal of Immunology Research. 2020:2020.
19. Manoussakis MN, Georgopoulou C, Zintzaras E, Spyropoulou M, Stavropoulou A, Skopouli FN, et al. Sjogren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjogren's syndrome. Arthritis Rheum. 2004;50(3):882-91.
20. Brito-Zeron P, Acar-Denizli N, Ng WF, Zeher M, Rasmussen A, Mandl T, et al. How immunological profile drives clinical phenotype of primary Sjogren's syndrome at diagnosis: analysis of 10,500 patients (Sjogren Big Data Project). Clin Exp Rheumatol. 2018;36 Suppl 112(3):102-12.
21. Mariette X, Criswell LA. Primary Sjogren's Syndrome. N Engl J Med. 2018;379(1):97.
22. Psianou K, Panagoulias I, Papanastasiou AD, de Lastic AL, Rodi M, Spantidea PI, et al. Clinical and immunological parameters of Sjogren's syndrome. Autoimmun Rev.
23. Pasoto SG, Adriano de Oliveira Martins V, Bonfa E. Sjogren's syndrome and systemic lupus erythematosus: links and risks. Open Access Rheumatol. 2019;11:33-45.
24. Li Y, Zhang K, Chen H, Sun F, Xu J, Wu Z, et al. A genome-wide association study in Han Chinese identifies a susceptibility locus for primary Sjogren's syndrome at 7q11.23. Nat Genet. 2013;45(11):1361-5.
25. Aggarwal R, Anaya JM, Koelsch KA, Kurien BT, Scofield RH. Association between Secondary and Primary Sjogren's Syndrome in a Large Collection of Lupus Families. Autoimmune Dis. 2015;2015:298506.
26. Mavragani CP, Nezos A, Sagalovskiy I, Seshan S, Kirou KA, Crow MK. Defective regulation of L1 endogenous retroelements in primary Sjogren's syndrome and systemic lupus erythematosus: Role of methylating enzymes. J Autoimmun. 2018;88:75-82.
27. Yang Y, Li Z, Wang L, Zhang F. The clinical and laboratory characteristics of Sjogren's syndrome that progresses to systemic lupus erythematosus: a retrospective case-control study. Int J Rheum Dis. 2013;16(2):173-7.
28. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum. 2002;46(3):741-7.
29. Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjogren's syndrome: a prospective cohort study. Arthritis Rheum. 2004;50(4):1262-9.
30. Nocturne G, Virone A, Ng WF, Le Guern V, Hachulla E, Corne D, et al. Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjogren's Syndrome. Arthritis Rheumatol. 2016;68(4):977-85.
31. M R-C, P B-Z, J Y, M A, R B, M R, et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. Rheumatology (Oxford, England). 2005;44(1).
32. Solans-Laqué R, López-Hernandez A, Bosch-Gil JA, Palacios A, Campillo M, VilardeLL-Tarres M. Risk, Predictors, and Clinical Characteristics of Lymphoma Development in Primary Sjögren's Syndrome. Seminars in Arthritis and Rheumatism. 2011;41(3).